Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
30.84
-0.18 (-0.58%)
At close: Jul 11, 2025, 4:00 PM
30.87
+0.03 (0.10%)
After-hours: Jul 11, 2025, 4:11 PM EDT
Surmodics Revenue
Surmodics had revenue of $28.09M in the quarter ending March 31, 2025, a decrease of -12.12%. This brings the company's revenue in the last twelve months to $121.58M, down -14.96% year-over-year. In the fiscal year ending September 30, 2024, Surmodics had annual revenue of $126.08M, down -4.91%.
Revenue (ttm)
$121.58M
Revenue Growth
-14.96%
P/S Ratio
3.61
Revenue / Employee
$312,532
Employees
389
Market Cap
441.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 126.08M | -6.51M | -4.91% |
| Sep 30, 2023 | 132.58M | 32.63M | 32.65% |
| Sep 30, 2022 | 99.95M | -5.19M | -4.93% |
| Sep 30, 2021 | 105.14M | 10.27M | 10.83% |
| Sep 30, 2020 | 94.86M | -5.21M | -5.21% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SRDX News
- 2 months ago - Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - Business Wire
- 2 months ago - Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - Business Wire
- 2 months ago - Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
- 3 months ago - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Business Wire
- 4 months ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 4 months ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters
- 5 months ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 5 months ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire